Bernard Mach		 NovImmune is a Geneva based, clinically active, drug development company focused on the development of therapeutic agents for immune-related disorders and inflammation.
NovImmune uniquely combines:

Core business is the development of fully human therapeutic monoclonal antibodies...
More


A clinically active company with its first fully human therapeutic monoclonal antibody in clinical development (Phase IIa clinical trial), and the second in GMP manufacturing, with a demonstrated ability to deliver one novel medically relevant therapeutic MAb as IND candidate every year.
Access to the entire pathway of monoclonal antibody development with the same partner, from target selection, high throughput MAb screening, and biological validation to the end of Phase II clinical trials. Fully human MAbs development in house using transgenic mice (Medarex) or phage display (CAT).
Access to novel classes of low molecular weight immunomodulatory and anti-inflammatory agents based on fully validated and proprietary targets.
More
SCIENTIFIC PLATFORMS: A Balanced Portfolio
 Fully Human Therapeutic MAbs

Fully human therapeutic MAbs against well validated medically relevant targets, focused on immune-related diseases and inflammation (Fully human MAb generated in house using either transgenic mice or phage display technology).
Research Research &
Pre-clinical Development		 Clinical Development
Phase I & II
LICENSE STRATEGY: License out at end of Phase IIa/Phase II or co-developdevelopment
 MHC Class II Inhibitors

Novel types of low molecular weight drugs as immunosuppressors, immunomodulators and anti-inflammatory agents.
Research Research & HTS
Hit/Lead
  Lead Optimisation Candidates
LICENSE STRATEGY: License out at lead optimisation stage to pharma
Mission
Business Strategy
Area of Expertise
Management
Board of Directors
Scientific Advisory Board (SAB)
Intellectual Property
NovImmune has a unique network of scientific, industrial and business connections in the field of immunology.

Collaboration Opportunities:
In- and Out- licensing.
© Novimmune 2008